Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELECTRA
2024-512878-98-00Phase 2Authorised
- Sponsor
- Stemline Therapeutics
- Start
- Oct 2024
- Modality
- Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label trial of elacestrant and abemaciclib in breast cancer, sponsored by Stemline Therapeutics. Primary endpoints: Recommended Phase 2 dose and Overall response rate. Planned start Oct 2024; status: authorised.
02
Drugs
elacestrantabemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-512878-98-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512878-98-00.